KRAS-Mutant Non-Small Cell Lung Cancer: An Emerging Promisingly Treatable Subgroup
文献类型：期刊论文
| 作者 | Xie, Mingying3; Xu, Xiaoling1,2,4; Fan, Yun1,2,4 |
| 刊名 | FRONTIERS IN ONCOLOGY
 |
| 出版日期 | 2021-05-03 |
| 卷号 | 11 |
| 关键词 | KRAS-mutant NSCLC targeted therapy immunotherapy AMG510 MRTX849 |
| ISSN号 | 2234-943X |
| DOI | 10.3389/fonc.2021.672612 |
| 通讯作者 | Fan, Yun(fanyun@zjcc.org.cn) |
| 英文摘要 | Lung cancer, the leading cause of cancer-related deaths worldwide, can be classified into small cell lung cancer and non-small cell lung cancer (NSCLC). NSCLC is the most common histological type, accounting for 85% of all lung cancers. Kirsten rat sarcoma viral oncogene (KRAS) mutations, common in NSCLC, are associated with poor prognosis, likely due to poor responses to most systemic therapies and lack of targeted drugs. The latest published clinical trial data on new small-molecule KRAS G12C inhibitors, AMG510 and MRTX849, indicate that these molecules may potentially help treat KRAS-mutant NSCLC. Simultaneously, within the immuno-therapeutic process, immune efficacy has been observed in those patients who have KRAS mutations. In this article, the pathogenesis, treatment status, progress of immunotherapy, and targeted therapy of KRAS-mutant NSCLC are reviewed. |
| WOS关键词 | INHIBITOR ; CONFERS |
| 资助项目 | Natural Scientific Foundation of China[81972718] ; Natural Scientific Foundation of Zhejiang Province, China[LY19H160007] |
| WOS研究方向 | Oncology |
| 语种 | 英语 |
| WOS记录号 | WOS:000651054400001 |
| 出版者 | FRONTIERS MEDIA SA |
| 资助机构 | Natural Scientific Foundation of China ; Natural Scientific Foundation of Zhejiang Province, China |
| 源URL | [http://ir.hfcas.ac.cn:8080/handle/334002/122092]  |
| 专题 | 中国科学院合肥物质科学研究院 |
| 通讯作者 | Fan, Yun |
| 作者单位 | 1.Univ Chinese Acad Sci, Canc Hosp, Dept Med Oncol, Zhejiang Canc Hosp, Hangzhou, Peoples R China 2.Zhejiang Canc Hosp, Dept Thorac Med Oncol, Hangzhou, Peoples R China 3.Zhejiang Chinese Med Univ, Dept Med Oncol, Clin Med Coll 2, Hangzhou, Peoples R China 4.Chinese Acad Sci, Inst Basic Med & Canc IBMC, Hangzhou, Peoples R China |
| 推荐引用方式 GB/T 7714 | Xie, Mingying,Xu, Xiaoling,Fan, Yun. KRAS-Mutant Non-Small Cell Lung Cancer: An Emerging Promisingly Treatable Subgroup[J]. FRONTIERS IN ONCOLOGY,2021,11. |
| APA | Xie, Mingying,Xu, Xiaoling,&Fan, Yun.(2021).KRAS-Mutant Non-Small Cell Lung Cancer: An Emerging Promisingly Treatable Subgroup.FRONTIERS IN ONCOLOGY,11. |
| MLA | Xie, Mingying,et al."KRAS-Mutant Non-Small Cell Lung Cancer: An Emerging Promisingly Treatable Subgroup".FRONTIERS IN ONCOLOGY 11(2021). |
入库方式： OAI收割
来源：合肥物质科学研究院
浏览0
下载0
收藏0
其他版本
除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。